MedTrace Logo

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

NCT00267930 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2008-12-18

No results posted yet for this study

Summary

This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration

Conditions

Interventions

DRUG

Vernakalant (oral)

DRUG

Placebo comparator

Sponsors & Collaborators

  • Advanz Pharma

    lead INDUSTRY

Principal Investigators

  • Greg Beatch, PhD · Advanz Pharma

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Completion
2006-08-31

Countries

  • United States
  • Canada
  • Denmark
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00267930 on ClinicalTrials.gov